Norgine launches Shield’s Feraccru in the UK
Norgine has launched Feraccru across the UK to treat patients with iron deficiency anaemia, having picked up rights to sell the drug from Shield Therapeutics earlier this year.
Read More
Tag: Norgine
Norgine buys rights to sell Shield’s iron deficiency therapy
Norgine has signed a deal with Shield Therapeutics allowing it to commercialise iron deficiency therapy Feraccru in Europe, Australia and New Zealand.
Read More
Norgine rejoins ABPI after eight year absence
European specialty group Norgine has renewed its membership with the Association of the British Pharmaceutical Industry after having cut ties with the organisation in October 2008.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
